| 0.6796 -0.031 (-4.42%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.84 | 1-year : | 0.99 |
| Resists | First : | 0.72 | Second : | 0.84 |
| Pivot price | 0.65  |
|||
| Supports | First : | 0.61 | Second : | 0.55 |
| MAs | MA(5) : | 0.68 |
MA(20) : | 0.64 |
| MA(100) : | 0.64 |
MA(250) : | 0.92 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 66.4 |
D(3) : | 74.5 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 2.92 | Low : | 0.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BRNS ] has closed above bottom band by 44.2%. Bollinger Bands are 7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.69 - 0.69 | 0.69 - 0.69 |
| Low: | 0.63 - 0.63 | 0.63 - 0.64 |
| Close: | 0.64 - 0.65 | 0.65 - 0.65 |
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Tue, 12 May 2026
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
Mon, 11 May 2026
Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - FinancialContent
Mon, 11 May 2026
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
Fri, 01 May 2026
Barinthus Biotherapeutics PLC expected to post a loss of 28 cents a share - Earnings Preview - TradingView
Thu, 30 Apr 2026
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments - GlobeNewswire
Thu, 30 Apr 2026
Analyst Flags High Risk in Barinthus Biotherapeutics’ Forward-Looking Statements and Guidance Reliability - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 13.1 (%) |
| Held by Institutions | 40.8 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -1.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.1 % |
| Return on Equity (ttm) | -65.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.4 |
| PEG Ratio | 0 |
| Price to Book value | 0.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|